A clinical prediction model to estimate the risk for coarctation of the aorta in the presence of a patent ductus arteriosus.

J Am Soc Echocardiogr

Department of Pediatrics, Thomas P. Graham Jr. Division of Pediatric Cardiology, Vanderbilt University Medical Center, and the Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee. Electronic address:

Published: December 2013

Background: Diagnosing coarctation of the aorta (CoA) in the presence of a patent ductus arteriosus (PDA) may require observation until PDA closure. The aim of this study was to create a model incorporating previously published indices to estimate the probability of neonatal CoA in the presence of a PDA.

Methods: A retrospective "investigation" cohort of 80 neonates was divided into two groups: (1) neonates with PDA and suspicion for CoA requiring observation to confirm the presence or absence of CoA and (2) neonates with PDA and confirmed diagnosis of either CoA or unobstructed aortic arch. Multivariate logistic regression was used to create the coarctation probability model (CPM), which was used to calculate a neonate's probability of CoA. The CPM was validated internally using bootstrapping and subsequently validated prospectively using a "validation" cohort of 74 neonates with PDA.

Results: The CPM had an area under the receiver operating characteristic curve of 0.96 and demonstrated good clinical significance in the risk stratification of neonates with PDA and CoA. No neonate with a CPM probability of <15% had CoA after PDA closure. Neonates with CPM probability < 15% were classified at low risk, between 15% and 60% at moderate risk, and >60% at high risk for CoA.

Conclusions: On the basis of these results, the authors recommend measurement of the CPM in all neonates with PDA. Those with CPM probability < 15% no longer require observation, which could decrease observation in as many as half of neonates with unobstructed aortic arches; those with CPM probabilities between 15% and 60% require follow-up imaging, while those with CPM probabilities > 60% should be observed as inpatients until PDA closure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915292PMC
http://dx.doi.org/10.1016/j.echo.2013.08.016DOI Listing

Publication Analysis

Top Keywords

neonates pda
16
coarctation aorta
8
presence patent
8
patent ductus
8
ductus arteriosus
8
coa presence
8
require observation
8
pda closure
8
cohort neonates
8
unobstructed aortic
8

Similar Publications

Unlabelled: Hemodynamically significant patent ductus arteriosus (hs-PDA) in very low birth weight (VLBW) infants continues to be an issue of research regarding the timing of treatment and which would be the most appropriate drug.

Objective: To assess the outcome of prolonged treatment with paracetamol in the closure of hemodynamically significant patent ductus arteriosus in preterm newborns.

Patients And Method: Retrospective study in VLBW infants with echocardiographic and clinical diagnosis of hs-PDA who received treatment with intravenous paracetamol at 15 mg/kg every 6 hours for 6 days.

View Article and Find Full Text PDF

Background: The issue of retreatment with surfactant of infants with respiratory distress syndrome (RDS) has been poorly investigated. Our aim was to identify possible clinical predictors of the need for multiple doses of surfactant in a large cohort of very preterm infants.

Methods: Data were analyzed from three previous studies on infants born between 25 and 31 weeks of gestation with RDS who were treated with surfactant.

View Article and Find Full Text PDF

The objective of this study is to evaluate the clinical application and primary outcome of transcatheter embolization using Amplatzer™ Vascular Plug (AVP) Type 2 and Type 4 in different congenital cardiovascular malformations. This is a single-center retrospective observational cohort study. We analyzed clinical and imaging data of 36 patients retrospectively who received transcatheter embolizations of the following malformations using AVP: systemic-to-pulmonary collateral arteries (SPCA), patent ductus arteriosus (PDA), ventricular septal defects (VSD), and aberrant pulmonary sequestration arteries (PSA).

View Article and Find Full Text PDF

Objective: To investigate the association between the secular decrease in treatment of patent ductus arteriosus (PDA ) and trends in neonatal mortality and morbidity in infants born at 26 0/7 to 28 6/7 weeks' gestation.

Study Design: A retrospective cohort study including infants born between 2012 and 2021 in continually participating hospitals in the NICHD Neonatal Research Network. The primary composite outcome was defined as surgical necrotizing enterocolitis, grade 2-3 bronchopulmonary dysplasia (BPD), severe intraventricular hemorrhage, or death.

View Article and Find Full Text PDF

Background: Bronchopulmonary dysplasia (BPD) poses a challenge in neonatal care. Previous literature recommended a hypothetical role for patent ductus arteriosus (PDA) in the development of BPD. This study explores the possible link between PDA and BPD, aiming to illuminate demographic and clinical factors influencing BPD development within the context of PDA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!